Vera Therapeutics (VERA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.07 (+0.14%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Vera Therapeutics (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $49.46
  • Market Cap

    $3.13 Billion
  • Total Outstanding Shares

    63.32 Million Shares
  • Total Employees

    82
  • Dividend

    No dividend
  • IPO Date

    May 14, 2021
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.veratx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$305.55 Million
Net Cash Flow From Operating Activities$-120.64 Million
Net Cash Flow From Investing Activities, Continuing$-185.09 Million
Net Cash Flow From Operating Activities, Continuing$-120.64 Million
Net Cash Flow$185000.00
Net Cash Flow, Continuing$185000.00
Net Cash Flow From Financing Activities, Continuing$305.55 Million
Net Cash Flow From Investing Activities$-185.09 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-134.38 Million
Revenues$0.00
Income/Loss From Continuing Operations Before Tax$-134.38 Million
Nonoperating Income/Loss$10.91 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Diluted Average Shares$54.12 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss$-134.38 Million
Preferred Stock Dividends And Other Adjustments$0.00
Basic Earnings Per Share$2.61
Other Operating Expenses$31.67 Million
Research and Development$113.61 Million
Operating Income/Loss$-145.28 Million
Income/Loss From Continuing Operations After Tax$-134.38 Million
Basic Average Shares$54.12 Million
Operating Expenses$145.28 Million
Net Income/Loss Attributable To Parent$-134.38 Million
Diluted Earnings Per Share$2.61

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$364.13 Million
Long-term Debt$50.47 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$18.22 Million
Noncurrent Liabilities$53.04 Million
Accounts Payable$4.60 Million
Liabilities$79.50 Million
Liabilities And Equity$368.56 Million
Equity Attributable To Parent$289.06 Million
Other Non-current Liabilities$2.57 Million
Fixed Assets$368000.00
Equity$289.06 Million
Other Non-current Assets$4.06 Million
Current Liabilities$26.46 Million
Wages$3.64 Million
Assets$368.56 Million
Noncurrent Assets$4.43 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.